Mesenchymal stem cells are studied for the treatment of Alzheimer’s disease

In May 2017, in USA the company “Longeveron”, specializing on regenerative medicine drugs announced about the beginning of phase 1 of the clinical trial on the evaluation of the safety, tolerability and efficacy of mesenchymal stem cells in the treatment of Alzheimer’s disease.

The trial is approved by the Data Monitoring Committee (DMC) in USA, which reviewed it towards safety, having analyzed the data on treatment of 5 patients with Alzheimer’s disease. In USA, Data Monitoring Committee is the independent group of experts, who regularly review the data from current clinical trials and report on the safety of project as well as it validity and scientific merit to the sponsor.

Dr. Barry Baumek, the principal investigator and director of the group of trials on the memory disorders of the Department of Neurology of the Miller School of Medicine of the Miami University concluded the following: “The treatment of the first 5 patients in our program showed that the application of mesenchymal stem cells in the treatment of Alzheimer’s disease is safe. Now we are going to continue enrollment to evaluate whether cell therapy is effective in this disorder, i.e. whether it inhibits the progression of the course of this disease.”

This study is the USA first clinical trial on the treatment of Alzheimer’s disease by means of administration of exogenous mesenchymal stem cells, derived from the bone marrow of adult donors.

The same stem cells may be derived from the umbilical cord blood, collected at childbirth.


No Comments Yet.

Leave a comment

You must be logged in to post a comment.